story of the week
Cabozantinib Plus Nivolumab and Ipilimumab for Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
N. Engl. J. Med 2023 May 11;388(19)1767-1778, TK Choueiri, T Powles, L Albiges, M Burotto, C Szczylik, B Zurawski, E Yanez Ruiz, M Maruzzo, A Suarez Zaizar, LE Fein, FA Schutz, DYC Heng, F Wang, F Mataveli, YL Chang, M van Kooten Losio, C Suarez, RJ MotzerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.